Expect margin momentum as Q2 follows Q1's operational leverage play
After a strong Q1—revenue growth of 9% with EBITDA surging 25%—Sharda Cropchem heads into Q2 FY27 (nine months from ATH but on track for full-year guidance). What to watch: whether operating leverage persists, how agrochemical mix holds up, and guidance sustainability on an oversold tape.
The setup
Sharda Cropchem enters Q2 FY27 on the back of a strong Q1: revenue ₹1,074 Cr (up 9% YoY), EBITDA ₹178 Cr (up 25%), with EBITDA margins expanding 220 basis points to 16.6%. The company reaffirmed 10–15% full-year revenue growth guidance and gross margins anchored around 35%. For Q2, on a run-rate basis, expect revenue in the ~₹1,100–1,120 Cr band, with EBITDA margins holding in the 16–17% range if operational leverage persists.
~₹1,100–1,120 Cr
Q1 was ₹1,074 Cr; modest sequential growth on-plan for 9% YoY growth run-rate
~16–17%
Q1 hit 16.6%; operating leverage and gross-margin strength to sustain this band
10–15% revenue growth
Reaffirmed on June 30 call; company remains on track through H1 results
₹767 Cr
Debt-free balance sheet as of Q1; no financing headwinds expected
A strong print would show Q2 revenue at or above ₹1,120 Cr (in line with 10%+ growth), EBITDA margins holding above 16%, and confirmation that the agrochemical business (₹915 Cr in Q1, up 8% YoY) is sustaining growth. A weak print would flag revenue below ₹1,050 Cr (signaling deceleration), margin compression below 15.5%, or downward guidance revision on the back of H1 execution or margin pressures.
On track for the year?
Yes, on the evidence so far. Through Q1, Sharda Cropchem is tracking 10–15% full-year revenue guidance. H1 revenue (Q1 + Q2 on-plan) would be ~₹2,200 Cr, placing the company ahead of a linear path through the ₹10–11.5 Cr range for full-year FY27. EBITDA growth (up 25% in Q1) has surprised to the upside, driven by gross-margin strength and operating leverage; if margins stabilize at 16–17%, the company should deliver mid-to-high teens EBITDA growth for the full year.
What the Street says
Since last quarter
Sep 28, 2026
Oct 1 to 48h post-result for Q2 FY27. Routine for result season.
Trading window closure
Oct 22, 2026
Oct 30, 2026 to approve unaudited standalone & consolidated results.
Board meeting notice
Jul 14, 2026
23rd AGM held Aug 14, 2026; routine governance.
AGM notice
Jul 14, 2026
BRSR filing
Insider activity: No pledges or significant promoter trading flagged in recent filings. Promoter ownership steady at 74.82% (as of Q1 FY27). FII ownership has ticked down from 5.48% (Q1 FY26) to 3.11% (Q1 FY27), tracking broader FII outflow from India equities; DII stable at ~9%. No material corporate actions pending.
What to watch on October 30
1 · Revenue & growth run-rate
Is Q2 revenue in the ₹1,050–1,150 Cr band, sustaining the ~9% YoY growth trajectory? A print below ₹1,050 Cr would flag deceleration.
2 · EBITDA margin hold
Can the company sustain 16%+ EBITDA margins in Q2, or does margin compress due to input costs or product mix? 15.5%–17% is the expected range.
3 · Agrochemical segment trend
The core business (Q1: ₹915 Cr, up 8% YoY) is the bellwether. Watch for growth acceleration or deceleration in this line.
4 · Full-year guidance reset
Will the company reaffirm 10–15% FY27 revenue growth, or narrow/revise based on H1 results? Any trim would signal caution heading into H2.
5 · Management commentary on demand
Listen for tone on global agrochemical demand, pricing power, and any margin-pressure signals from input costs or FX headwinds.
Sharda Cropchem enters Q2 as a momentum story on operating leverage. Q1's 25% EBITDA growth on 9% revenue signals operational discipline and pricing/mix advantage. The company is on track for 10–15% FY27 revenue guidance, and the Street sees ample upside (median target ₹1,305 vs. current ₹631). A clean Q2—revenue ₹1,050–1,150 Cr, margins 16%+—should confirm the trajectory. Downside risks center on agrochemical demand softness, margin pressure from input inflation, or early FY27 guidance trim. Watch for tone from management on global demand and any revisions to H2 expectations.
This is a pre-result preview grounded in Q1 performance, guidance, and analyst commentary. No forecast of the unreleased Q2 result is presented as fact. The Street view is consensus-bullish, but stock technicals (down 51% from ATH, RSI 18.7) suggest caution on sentiment near-term.
Informational and educational content only. Not investment advice.